Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia

Urology

Volumn 67, Issue 1, 2006, Pages 84-88

  Slawin, Kevin M ^a,b   Kattan, Michael W ^b   Roehrborn, Claus G ^c   Wilson, Timothy ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Oncovance ^*

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FLOW RATE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REGRESSION ANALYSIS; URINE RETENTION;

ACUTE DISEASE; AZASTEROIDS; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATIC HYPERPLASIA; URINARY RETENTION;

EID: 30344437996     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.07.013     Document Type: Article

References (16)

1. M. Emberton, G.L. Andriole, J. de la Rosette Benign prostatic hyperplasia a progressive disease of aging men Urology 61 2003 267 273
2. S.J. Jacobsen, C.J. Girman, H.A. Guess Natural history of prostatism longitudinal changes in voiding symptoms in community dwelling men J Urol 155 1996 595 600
3. H.M. Arrighi, E.J. Metter, J.A. Guess Natural history of benign prostatic hyperplasia and risk of prostatectomy Urology 37 1991 4 8
4. S.J. Jacobsen, D.J. Jacobson, C.J. Girman Natural history of prostatism risk factors for acute urinary retention J Urol 158 1997 481 487
5. J.D. McConnell, R. Bruskewitz, P. Walsh Finasteride Long-Term Efficacy and Safety Study Group The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia N Engl J Med 338 1998 557 563
6. C.G. Roehrborn, P. Boyle, J.C. Nickel Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441
7. C.G. Roehrborn, J. McConnell, J. Bonilla Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia PROSCAR Long-Term Efficacy and Safety Study J Urol 163 2000 13 20
8. C.G. Roehrborn, J.D. McConnell, M. Lieber PLESS Study Group Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 53 1999 473 480
9. B. Efron, R. Tibshirani An Introduction to the Bootstrap. 1993 Chapman & Hall New York
10. J.A. Eastham, M.W. Kattan, P.T. Scardino Nomograms as predictive models Semin Urol Oncol 20 2002 108 115
11. M.W. Kattan Comparison of Cox regression with other methods for determining prediction models and nomograms J Urol 170 2003 S6 S10
12. S.J. Jacobsen, C.J. Girman, J.A. Guess Natural history of prostatism longitudinal changes in voiding symptoms in community dwelling men J Urol 155 1996 595 600
13. C.G. Roehrborn, P. Boyle, D. Bergner PLESS Study Group Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate results of a four-year, randomized trial comparing finasteride versus placebo Urology 54 1999 662 669
14. S.J. Jacobsen, D.J. Jacobson, C.J. Girman Treatment for benign prostatic hyperplasia among community dwelling men the Olmsted County study of urinary symptoms and health status J Urol 162 1999 1301 1306
15. C.G. Roehrborn, J.D. McConnell, B. Saltzman Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes Eur Urol 42 2002 1 6
16. Slawin KM, McConnell JD, and Roehrborn CG: Development of a nomogram to predict acute urinary retention or BPH-related surgery with or without medical therapy in men with BPH based on data from the MTOPS trial (abstract). Presented at the 2005 Meeting of the American Urological Association, San Antonio, Texas.